epiCam, a camera for screening diabetic retinopathy being developed by Epipole, may save sight of millions

Epipole is building a mass market diabetic retinopathy monitoring and screening platform usable by both clinicians and non-clinicians in a home or social environment. The system will provide monitoring capabilities as well as a portable, low cost tool for clinicians for tele-medicine applications.

The platform consists of three parts:

1. A retinal fundus camera tuned specifically to this task.
2. Safe Cloud based storage for all images.
3. A sophisticated piece of software usable by non-clinicians which can run in limited-compute environments.

Diabetes, as is well known, has become a major public health concern. A significant number of those affected with this disease are likely to suffer from diabetic retinopathy. To understand the significance of the problem we face, here are some statistics from ARVO 2011 for the year 2010 (with expected numbers in 2030 in parentheses). 

• 100.8 (154.9) million people with diabetic retinopathy

• 20.6 (31.7) million with proliferative diabetic retinopathy

• 21.3 (32.8) million with diabetic macular edema and

• 33.4 (51.3) million with vision-threatening diabetic retinopathy.

More about epiCam here.